ArticlePloS one2014
Near-infrared imaging of adoptive immune cell therapy in breast cancer model using cell membrane labeling.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Recent advances in non-invasiveBiomaterials science · 2025Review
- Smart probes for optical imaging of T cells and screening of anti-cancer immunotherapies.Chemical Society reviews · 2023Review
- Thermoresponsive Liposomes for Photo-Triggered Release of Hypericin Cyclodextrin Inclusion Complex for Efficient Antimicrobial Photodynamic Therapy.ACS applied materials & interfaces · 2022Article
- Cancer therapy in mice using a pure population of CD8Cancer immunology, immunotherapy : CII · 2021Article
- Non-invasive synchronous monitoring of neutrophil migration using whole body near-infrared fluorescence-based imaging.Scientific reports · 2021Article
- Near-infrared fluorescence imaging in immunotherapy.Advanced drug delivery reviews · 2020Review
- Fabrication and Characterization of Tumor Nano-Lysate as a Preventative Vaccine for Breast Cancer.Langmuir : the ACS journal of surfaces and colloids · 2020Article
- New Developments in Imaging Cell-Based Therapy.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019Review
- Dendritic cell trafficking in tumor-bearing mice.Cancer immunology, immunotherapy : CII · 2018Article
- TricarbocyanineChemical science · 2018Article
- Off-Target and Tumor-Specific Accumulation of Monocytes, Macrophages and Myeloid-Derived Suppressor Cells after Systemic Injection.Neoplasia (New York, N.Y.) · 2018Article
- The Immunoimaging Toolbox.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Review
- Primary T cells for mRNA-mediated immunotoxin delivery.Gene therapy · 2018Article
- Detection of intramyocardially injected DiR-labeled mesenchymal stem cells by optical and optoacoustic tomography.Photoacoustics · 2017Article
- Preclinical imaging methods for assessing the safety and efficacy of regenerative medicine therapies.NPJ Regenerative medicine · 2017Review
- Surface biotinylation of cytotoxic T lymphocytes for in vivo tracking of tumor immunotherapy in murine models.Cancer immunology, immunotherapy : CII · 2016Article
- Grapefruit-derived Nanovectors Delivering Therapeutic miR17 Through an Intranasal Route Inhibit Brain Tumor Progression.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- Advances in Molecular Imaging Strategies forBioMed research international · 2016Review
- Imaging Biomarkers in Immunotherapy.Biomarkers in cancer · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
The overall objective of this study is to non-invasively image and assess tumor targeting and retention of directly labeled T-lymphocytes following their adoptive transfer in mice. T-lymphocytes obtained from draining lymph nodes of 4T1 (murine breast cancer cell) sensitized BALB/C mice were activated in-vitro with Bryostatin/Ionomycin for 18 hours, and were grown in the presence of Interleukin-2 for 6 days. T-lymphocytes were then directly labeled with 1,1-dioctadecyltetramethyl indotricarbocyanine Iodide (DiR), a lipophilic near infrared fluorescent dye that labels the cell membrane. Assays for viability, proliferation, and function of labeled T-lymphocytes showed that they were unaffected by DiR labeling. The DiR labeled cells were injected via tail vein in mice bearing 4T1 tumors in the flank. In some cases labeled 4T1 specific T-lymphocytes were injected a week before 4T1 tumor cell implantation. Multi-spectral in vivo fluorescence imaging was done to subtract the autofluorescence and isolate the near infrared signal carried by the T-lymphocytes. In recipient mice with established 4T1 tumors, labeled 4T1 specific T-lymphocytes showed marked tumor retention, which peaked 6 days post infusion and persisted at the tumor site for up to 3 weeks. When 4T1 tumor cells were implanted 1-week post-infusion of labeled T-lymphocytes, T-lymphocytes responded to the immunologic challenge and accumulated at the site of 4T1 cell implantation within two hours and the signal persisted for 2 more weeks. Tumor accumulation of labeled 4T1 specific T-lymphocytes was absent in mice bearing Meth A sarcoma tumors. When lysate of 4T1 specific labeled T-lymphocytes was injected into 4T1 tumor bearing mice the near infrared signal was not detected at the tumor site. In conclusion, our validated results confirm that the near infrared signal detected at the tumor site represents the DiR labeled 4T1 specific viable T-lymphocytes and their response to immunologic challenge can be imaged in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.